Table 1 Participant demographics
From: Impact of cerebral blood flow and amyloid load on SUVR bias
[18F]flutemetamol | [18F]florbetaben | |||||
|---|---|---|---|---|---|---|
All (N = 90) | Aβ-negative (N = 71) | Aβ-positive (N = 19) | All (N = 31) | Aβ-negative (N = 19) | Aβ-positive (N = 12) | |
Age | 67.2 ± 6.3 | 66.2 ± 6.3** | 70.7 ± 4.7 | 67.3 ± 7.4 | 66.0 ± 6.7 | 69.5 ± 8.2 |
Females % | 54.4 | 57.7 | 42.1 | 67.7 | 73.7 | 58.3 |
MMSE | 28.9 ± 1.4 | 29.2 ± 1.1 | 28.2 ± 2.1 | 29.1 ± 1.3 | 29.4 ± 0.8 | 28.7 ± 1.8 |
APOE-ε4 + % | 41.6 | 34.3* | 68.4 | 35.5 | 15.8* | 66.7 |
SUVR | 1.51 ± 0.3 | 1.41 ± 0.1** | 1.86 ± 0.3 | 1.48 ± 0.2 | 1.36 ± 0.1** | 1.66 ± 0.3 |
DVR | 1.23 ± 0.1 | 1.18 ± 0.1** | 1.41 ± 0.2 | 1.26 ± 0.2 | 1.18 ± 0.1** | 1.40 ± 0.2 |
R1 | 1.00 ± 0.1 | 1.00 ± 0.1 | 0.97 ± 0.1 | 0.96 ± 0.2 | 0.96 ± 0.1 | 0.95 ± 0.1 |
Centre | A,B,C,D | A,B,C,D | A,B,C | A | A | A |
Inj. dose (MBq) | 186.2 ± 10.4 | 188.8 ± 10.1 | 184.0 ± 7.7 | 282.9 ± 19.7 | 284.4 ± 17.9 | 280.5 ± 22.9 |